European Journal of Chemistry 2015, 6(4), 422-429 | doi: https://doi.org/10.5155/eurjchem.6.4.422-429.1313 | Get rights and content

Issue cover





  Open Access OPEN ACCESS | Open Access PEER-REVIEWED | RESEARCH ARTICLE | DOWNLOAD PDF | VIEW FULL-TEXT PDF | TOTAL VIEWS

Stability-indicating HPLC and PLS chemometric methods for the determination of acemetacin in presence of its degradation products and impurities


Amira Mohamed Kessiba (1,*) , Maha Abdel Monen Hegazy (2) , Mohamed Mohamed Abdelkawy (3) , Ahmed Emad El Gendy (4)

(1) Pharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, KM 28, Cairo, Egypt
(2) Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, 11562, Cairo, Egypt
(3) Analytical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, 11562, Cairo, Egypt
(4) Pharmaceutical Chemistry Department, Faculty of Pharmacy, Misr International University, KM 28, Cairo, Egypt
(*) Corresponding Author

Received: 23 Aug 2015 | Accepted: 19 Sep 2015 | Published: 31 Dec 2015 | Issue Date: December 2015

Abstract


Two stability-indicating methods were developed and validated for the quantitative determination of acemetacin (ACM) in presence of its degradation products and impurities. The first method was based on separation of ACM from its degradation products and impurities by RP-HPLC on Inertsil C8 column (150 × 4.6 mm i.d) using a mobile phase composed of 0.02 M phosphate buffer: methanol (35:65, v:v, pH = 6.5). The flow rate was adjusted at 1 mL/min and quantification was achieved with UV detection at 245 nm using meloxicam as internal standard. The second method was based on multivariate spectrophotometric analysis using partial least square regression model. The drug was subjected to acid, base, oxidative and thermal stress conditions and the degradation products were identified. The developed methods have the requisite accuracy, selectivity, sensitivity and precision to assay ACM in presence of its degradation products and impurities either in bulk powder or in pharmaceutical dosage form. The results obtained for the analysis of ACM in its pure form by the proposed methods were statistically compared to those obtained by applying a reported HPLC method. The statistical comparison showed that there is no significant difference between the proposed methods and the reported one with respect to accuracy and precision.


Keywords


HPLC; Impurities; Acemetacin; PLS regression model; Degradation products; Stability indicating methods

Full Text:

PDF
PDF    Open Access

DOI: 10.5155/eurjchem.6.4.422-429.1313

Links for Article


| | | | | | |

| | | | | | |

| | | |

Related Articles




Article Metrics

icon graph This Abstract was viewed 1264 times | icon graph PDF Article downloaded 429 times


Citations

/


[1]. Maha Mahmoud Abou-El Alamin
Ultra-performance liquid chromatography coupled to electrospray ionization-tandem mass spectrometric method for simultaneous determination of acemetacin in presence of its metabolite indomethacin and degradation products
European Journal of Chemistry  7(2), 213, 2016
DOI: 10.5155/eurjchem.7.2.213-216.1434
/


[2]. Mohamed A. Abdelgawad, Asmaa I. Owis, Nada S. Abdelwahab
Design and optimization of a reversed-phase HPLC with diode array detection method for the determination of acemetacin and its toxic impurities using experimental design
Separation Science Plus  1(4), 244, 2018
DOI: 10.1002/sscp.201700045
/


[3]. Eman M Moaaz, Ezzat M Abdel-Moety, Mamdouh R Rezk, Ahmed S Fayed
Eco-Friendly Chromatographic Methods for Determination of Acemetacin and Indomethacin; Greenness Profile Assessment
Journal of AOAC INTERNATIONAL  , , 2021
DOI: 10.1093/jaoacint/qsab085
/


References


[1]. Jones, R. W.; Collins, A. J.; Notarianni, L. J.; Sedman, E. Brit. J. Clin. Pharm. 1991, 31, 543-545.
http://dx.doi.org/10.1111/j.1365-2125.1991.tb05577.x

[2]. Hazleman, B.; Bernstein, R. M. Curr. Med. Res. Opin. 1993, 13, 119-126.
http://dx.doi.org/10.1185/03007999309111540

[3]. Chou, C. T.; Tsai, Y. Y. Int. J. Clin. Pharm. Res. 2002, 22, 1-6.
http://dx.doi.org/10.1002/j.1552-4604.1982.tb05701.x

[4]. Heitar, A.; Tausch, G.; Eberi, R. Arzneim Forsch 1980, 30, 1460-1463.

[5]. Lonauer, G.; Wirth, W. Arzneim Forsch 1980, 30, 1440-1444.

[6]. Brackertz, D.; Muller, M. Therapiewoche 1982, 32, 2493-2498.

[7]. Saul, P. A.; Korlipara, K. Curr. Med. Res. Opin. 1991, 12, 332-341.
http://dx.doi.org/10.1185/03007999109112669

[8]. Tavares, I. A.; Bennett, A. Int. J. Tiss. Reac. 1993, 15, 49-53.

[9]. Chavez-Pina, A. E.; McKnight, W.; Dicay, M.; Castaneda-Hernandez, G.; Wallace, J. L. Brit. J. Pharm. 2007, 152, 930-938.
http://dx.doi.org/10.1038/sj.bjp.0707451

[10]. Arcos, M. J.; Ortiz, M. C.; Villahoz, B.; Sarabia, L. A. Anal. Chim. Acta 1997, 339, 63-77.
http://dx.doi.org/10.1016/S0003-2670(96)00438-2

[11]. Castro, B.; Gameiro, P.; Lima, J. L. F. C.; Matos, C.; Reis, S. Mat. Sci. Eng. C 2001, 18, 71-78.
http://dx.doi.org/10.1016/S0928-4931(01)00372-1

[12]. Zouvelekis, D.; Yannakopoulou, K.; Mavridis, I. M.; Antoniadou, V. E. Carb. Res. 2002, 337, 1387-1395.
http://dx.doi.org/10.1016/S0008-6215(02)00174-X

[13]. Auer, M. E.; Griesser, U. J.; Sawatzki, J. J. Mol. Struct. 2003, 661-662, 307-317.
http://dx.doi.org/10.1016/j.molstruc.2003.09.002

[14]. Ozbakan, H.; Palabiyik, I. M.; Caglayan, M. G.; Onur, F. Turk. J. Pharm. Sci. 2009, 6, 163-176.

[15]. Schollnhammer, G.; Dell, H. D.; Doersing, K.; Kamp, R. J. Chrom. B: Biom. Sci. App. 1986, 375, 331-338.

[16]. Notarianni, L. J. J. Chrom. 1987, 413, 305-308.

[17]. Jones, R. W.; Collins, A. J.; Notarianni, L. J.; Sedman, E. Brit. J. Clin. Pharm. 1991, 31, 543-545.
http://dx.doi.org/10.1111/j.1365-2125.1991.tb05577.x

[18]. Hu, Y. Q.; Lui, H. C.; Hou, Y. N.; Wang, J. Chinese J. Clin. Pharm. 1999, 3, 203-205.

[19]. Hu, Y. Q.; Lui, H. C.; Ma, R.; Wang, J.; Hou, Y. N. Se Pu 1999, 17, 586-587.

[20]. Escuder, G. L.; Martin, B. Y.; Sagrado, S.; Villanueva, C. R. M.; Medina, H. M. J. Chromatographia 2002, 55, 283-288.
http://dx.doi.org/10.1007/BF02491660

[21]. Martinez, A. C.; Escuder, G. L.; Sagrado, S.; Villanueva, C. R. M.; Medina, H. M. J. J. Pharm. Biom. Anal. 2004, 36, 393-399.
http://dx.doi.org/10.1016/j.jpba.2004.06.011

[22]. Wei, W.; Yu, X.; Ju, H. J. Chrom. Sci. 2004, 42, 155-160.
http://dx.doi.org/10.1093/chromsci/42.3.155

[23]. Ban, E.; Cho, J. H.; Jang, D. J.; Piao, X. L.; Kim, C. K. J. Liq. Chrom. Rel. Techn. 2005, 28, 1593-1604.
http://dx.doi.org/10.1081/JLC-200058377

[24]. Li, D. M.; Lu, W. L.; Wang, X. Q.; Wang, J. C.; Zhang, H.; Zhang, R. J.; Wang, G. L.; Zhang, X.; Zhang, Q. J. Heal. Sci. 2005, 51, 308-316.
http://dx.doi.org/10.1248/jhs.51.308

[25]. Pina, A. E. C.; Favari, L.; Hernandez, G. C. Ann. Hepat. 2009, 8, 141-147.

[26]. Hu, T.; Peng, T.; Li, X. J.; Chen, D. D.; Dai, H. H.; Deng, X. J.; Yue, Z. F.; Wang, G. M.; Shen, J. Z.; Xia, X.; Ding, S. Y.; Zhou, Y. N.; Zhu, A. L.; Jiang, H. Y. J. Chromatogr. A 2012, 1219, 104-113.
http://dx.doi.org/10.1016/j.chroma.2011.11.009

[27]. Palacios, J. L.; Arcos, J.; Batanero, P. S. J. Pharm. Biom. Anal. 1988, 6, 963-968.
http://dx.doi.org/10.1016/0731-7085(88)80117-1

[28]. Reguera, C.; Arcos, M. J.; Ortiz, M. C. Talanta 1998, 46, 1493-1505.
http://dx.doi.org/10.1016/S0039-9140(98)00024-1

[29]. Reguera, C.; Ortiz, M. C.; Arcos, M. J. Electroanalysis 2002, 14, 1699-1706.
http://dx.doi.org/10.1002/elan.200290013

[30]. Naguib, I. A.; AbdelAleem, E. A.; Zaazaa, H.; Hussein, E. A. Eur. J. Chem. 2014, 5, 219-226.
http://dx.doi.org/10.5155/eurjchem.5.2.219-226.966

[31]. Wold, S.; Sjostrom, M. Chemom. Intel. Lab. Syst. 1998, 44, 3-4.
http://dx.doi.org/10.1016/S0169-7439(98)00075-6

[32]. Lotfy, H. M; Abdel-Monem H. M.; Abdel-Gawad, S. A. Eur. J. Chem. 2013, 4, 414-421.
http://dx.doi.org/10.5155/eurjchem.4.4.414-421.829

[33]. Matlab; Ver. 7.0.1., Mathworks Inc., 2004.

[34]. Barry, M.; Wise & NB. Gallagher; PLS_Toolbox 2.1, Eigenvector Research Inc., 2001.

[35]. Krzek, J.; Starek, M. J. AOAC Int. 2001, 84, 1703-1706.

[36]. Novakova, L.; Matysova, L.; Havlikova, L.; Solich, P. J. Pharm. Biom. Anal. 2005, 37, 899-905.
http://dx.doi.org/10.1016/j.jpba.2004.09.012

[37]. Garcia, B.; Hoyuelos, F. J.; Ibeas, S.; Leal. J. M. J. Org. Chem. 2012, 71, 3718-3726.
http://dx.doi.org/10.1021/jo052561k

[38]. British Pharmacopoeia; British Pharmacopoeia Commission; The stationary Office, 2012.

[39]. Clarke's Analysis of Drugs and Poisons, London: Pharmaceutical Press. Electronic version, 2005.

[40]. Gnehm, R.; Weber, R. Patentgenius 1985, Patent US4503237.

[41]. Lonauer, G.; Wirth, W. Arzneim Forsch 1980, 30, 1440-1444.

[42]. Brackertz, D.; Muller, M. Therapiewoche 1982, 32, 2493-2498.

[43]. Clarke's Analysis of Drugs and Poisons, 3rd ed.; Pharmaceutical press, London, United Kingdom 2004.

[44]. International Conference of Harmonization of technical requirements for registration of pharmaceuticals for human use (ICH), www.nihs.go.jp, Center for Drug Evaluation and Research, U. S. Food and Drug Administration. Reviewer Guidance, Validation of Chromatographic Methods; FDA, Rockville, 1994.

[45]. Lundstedt, T.; Seifert, E.; Abramo, L.; Thelin, B.; Nystrom, A.; Pettersen, J.; Bergman, R. Chemom. Intell. Lab. Syst. 1998, 42, 3-40.
http://dx.doi.org/10.1016/S0169-7439(98)00065-3

[46]. Haaland, D. M.; Thomas, E. V. Anal. Chem. 1988, 60, 1193-1202.
http://dx.doi.org/10.1021/ac00162a020


How to cite


Kessiba, A.; Hegazy, M.; Abdelkawy, M.; El Gendy, A. Eur. J. Chem. 2015, 6(4), 422-429. doi:10.5155/eurjchem.6.4.422-429.1313
Kessiba, A.; Hegazy, M.; Abdelkawy, M.; El Gendy, A. Stability-indicating HPLC and PLS chemometric methods for the determination of acemetacin in presence of its degradation products and impurities. Eur. J. Chem. 2015, 6(4), 422-429. doi:10.5155/eurjchem.6.4.422-429.1313
Kessiba, A., Hegazy, M., Abdelkawy, M., & El Gendy, A. (2015). Stability-indicating HPLC and PLS chemometric methods for the determination of acemetacin in presence of its degradation products and impurities. European Journal of Chemistry, 6(4), 422-429. doi:10.5155/eurjchem.6.4.422-429.1313
Kessiba, Amira, Maha Abdel Monen Hegazy, Mohamed Mohamed Abdelkawy, & Ahmed Emad El Gendy. "Stability-indicating HPLC and PLS chemometric methods for the determination of acemetacin in presence of its degradation products and impurities." European Journal of Chemistry [Online], 6.4 (2015): 422-429. Web. 17 Oct. 2021
Kessiba, Amira, Hegazy, Maha, Abdelkawy, Mohamed, AND El Gendy, Ahmed. "Stability-indicating HPLC and PLS chemometric methods for the determination of acemetacin in presence of its degradation products and impurities" European Journal of Chemistry [Online], Volume 6 Number 4 (31 December 2015)

The other citation formats (EndNote | Reference Manager | ProCite | BibTeX | RefWorks) for this article can be found online at: How to cite item



DOI Link: https://doi.org/10.5155/eurjchem.6.4.422-429.1313

CrossRef | Scilit | GrowKudos | Researchgate | Publons | Microsoft | scibey | Scite | Lens | OUCI

WorldCat Paperbuzz | LibKey Citeas | Dimensions | Semanticscholar | Plumx | Kopernio | Zotero | Mendeley

ZoteroSave to Zotero MendeleySave to Mendeley



European Journal of Chemistry 2015, 6(4), 422-429 | doi: https://doi.org/10.5155/eurjchem.6.4.422-429.1313 | Get rights and content

Refbacks

  • There are currently no refbacks.




Copyright (c)





© Copyright 2010 - 2021  Atlanta Publishing House LLC All Right Reserved.

The opinions expressed in all articles published in European Journal of Chemistry are those of the specific author(s), and do not necessarily reflect the views of Atlanta Publishing House LLC, or European Journal of Chemistry, or any of its employees.

Copyright 2010-2021 Atlanta Publishing House LLC. All rights reserved. This site is owned and operated by Atlanta Publishing House LLC whose registered office is 2850 Smith Ridge Trce Peachtree Cor GA 30071-2636, USA. Registered in USA.